Summit: Phase III Trial Of Ivonescimab Plus Chemotherapy Shows Positive Results In EGFR-Mutant NSCLC

Summit Therapeutics' Phase III HARMONi trial of ivonescimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NSCLC) met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 48% compared to chemotherapy alone. While the trial also showed a positive trend in overall survival, a statistically significant overall survival benefit is necessary for FDA marketing authorization, impacting Summit's BLA filing considerations. Ivonescimab, a bispecific antibody combining PD-1 and VEGF blockade, showed consistent PFS benefit in both Asian and Western patients.

Analysis

Summit Therapeutics (SMMT) reported positive topline results from its Phase III HARMONi trial for ivonescimab in combination with chemotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). The trial successfully met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS), with ivonescimab plus chemotherapy reducing the risk of disease progression or death by 48% compared to chemotherapy alone. This outcome is a significant clinical milestone for the novel, potential first-in-class bispecific antibody that targets both PD-1 and VEGF. Notably, the PFS benefit was consistent across both Asian and ex-Asia patient sub-populations in this multiregional study, which randomized approximately 38% of patients from Western countries. However, while the other primary endpoint, overall survival (OS), showed a positive trend, the U.S. Food & Drug Administration (FDA) has indicated that a statistically significant OS benefit is necessary for marketing authorization. This requirement will influence Summit's strategy regarding the timing of its planned Biologics License Application (BLA) filing, introducing a degree of regulatory uncertainty despite the strong PFS data and consistent OS results observed between the global HARMONi study and the single-region HARMONi-A study.

Key Decisions for Investors

• Investors should view the strong PFS results as a significant de-risking event for ivonescimab, but closely monitor upcoming communications regarding the overall survival data maturation and Summit's BLA filing strategy given the FDA's requirement for statistically significant OS.
• Consider the potential for substantial market appreciation if ivonescimab overcomes the OS hurdle, given its demonstrated efficacy and first-in-class potential in a challenging NSCLC patient population, but remain cognizant of the binary risk associated with the OS endpoint.
• Evaluate Summit's financial position and potential need for further funding as it navigates the BLA submission process and prepares for potential commercialization, factoring in the timeline implications of the OS data requirement.